Skip To Main Content
Barb Melosky on Muck Rack

Barb Melosky

As seen in: MDPI, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barb

Contact Barb, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Confirmation of Recurrent Lung Cancer Following Resection Using Liquid Biopsy, a Proof-of-Concept Real-World Study

|
By Julia R Naso, Stephen Yip, Curtis B Hughesman, Barb Melosky
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Current Oncology | Free Full-Text | The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis

|
By Anna L McGuire, Melissa K. McConechy, Barb Melosky, John English
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited.
Open in Who Shared Issue with article?

Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer

|
By Anna L McGuire, Curtis B Hughesman, Melissa K. McConechy, Barb Melosky
| Future Medicine Verified
Lung cancer remains the number one cause of cancer death globally [1,2]. Unfortunately, in an unscreened population, the majority of patients diagnosed with lung cancer (80%) present in stage III/IV [3,4]. Patients with the best prospect for cure include those with early stage (I/II) NSCLC undergoing curative intent surgical therapy. These early-stage patients have no clinical or radiological signs of overt cancer.
Open in Who Shared Issue with article?
See all 3 articles